Biaryl scaffold-focused virtual screening for anti-aggregatory and neuroprotective effects in Alzheimers disease

Cited 17 time in Web of Science Cited 15 time in Scopus

Khalid, Sidra; Zahid, Muhammad A; Ali, Hussain; Kim, Yeong S.; Khan, Salman

Issue Date
BioMed Central
BMC Neuroscience, 19(1):74
Computational analysisAlzheimerBiaryl scafoldNeuroprotection
Alzheimers disease (AD) is a primary cause of dementia in ageing population affecting more than 35 million people around the globe. It is a chronic neurodegenerative disease caused by defected folding and aggregation of amyloid beta (Aβ) protein. Aβ is formed by the cleavage of membrane embedded amyloid precursor protein (APP) by using enzyme transmembrane aspartyl protease, β-secretase. Inhibition of β-secretase is a viable strategy to prevent neurotoxicity in AD. Another strategy in the treatment of AD is inhibition of acetylcholinesterase. This inhibition reduces the degradation of acetylcholine and temporarily restores the cholinergic function of neurons and improves cognitive function. Monoamine oxidase and higher glutamate levels are also found to be linked with Aβ peptide related oxidative stress. Oxidative stress leads to reduced activity of glutamate synthase resulting in significantly higher level of glutamate in brain. The aim of this study is to perform in silico screening of a virtual library of biaryl scaffold containing compounds potentially used for the treatment of AD. Screening was done against the primary targets of AD therapeutics, acetylcholinesterase, β-secretase (BACE1), Monoamine oxidases (MAO) and N-Methyl-D-aspartate (NMDA) receptor. Compounds were screened for their inhibitory potential by employing molecular docking approach using AutoDock vina. Binding energy scores were embodied in the heatmap to display varies strengths of interactions of the ligands targeting AD.

Several ligands showed notable interaction with at least two targets, but the strong interaction with all the targets is shown by very few ligands. The pharmacokinetics of the interacting ligands was also predicted. The interacting ligands have good drug-likeness and brain availability essential for drugs with intracranial targets.

These results suggest that biaryl scaffold may be pliable to drug development for neuroprotection in AD and that the synthesis of further analogues to optimize these properties should be considered.
Files in This Item:
Appears in Collections:
College of Pharmacy (약학대학)Natural Products Research Institute(천연물과학연구소)Journal Papers (저널논문_천연물과학연구소)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.